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The Intensive Supportive Care plus Immunosuppression in IgA Nephropathy (STOP-IgAN) trial 
was designed to investigate the outcomes of immunosuppressive therapy, when added to 
maximal supportive care, in patients with IgA nephropathy (IgAN). This was a multicentre, open-
label, randomised, controlled trial with a two-group, parallel group design.  
 
Following screening, 337 participants were recruited from 32 nephrology centres across 
Germany.  The main inclusion criteria were biopsy confirmed primary IgAN; age 18 to 70; and a 
proteinuria level above 0.75g/day plus hypertension, impaired renal function (estimated 
glomerular filtration rate [eGFR] <90ml/min/1.73m2), or both. Patients with eGFR 
<30ml/minute/1.73m2, those with rapidly progressive crescentic IgAN, secondary IgAN and 
other chronic renal diseases, or who had previously received immunosuppression were 
excluded.  
 
The first stage of the trial involved a six-month run-in phase where all patients received intensive 
supportive care including Renin Angiotensin System (RAS) blockade to lower BP to a target 
below 125/70mmHg. If proteinuria persisted above 0.75g/day once this target BP was achieved, 
the dose of RAS blocker (either angiotensin converting enzyme inhibitor [ACEI], angiotensin 
receptor blocker [ARB] or both) was increased as tolerated up to the maximum approved dosage. 
Participants were seen seven times during this period. 34% of patients had a response to 
supportive care during this period with proteinuria falling to below 0.75g/day. These responsive 
patients were excluded from the randomisation phase of the study. 
 
Following the run-in phase, 162 participants with persistent proteinuria more than 0.75g/day 
but less than 3.5g/day were randomised to the 3-year study phase. These participants were 
randomly assigned either to continue with maximal supportive care alone (80 participants), or to 
receive maximal supportive care plus immunosuppressive therapy (82 participants). 
 
Depending on the eGFR, the immunosuppression given in the immunosuppression arm of the 
study varied. Patients with eGFR between 30 and 59ml/min/1.73m2 received cyclophosphamide 
(1.5mg/kilogram/day) for 3 months, followed by azathioprine (1.5mg/kg/day) during months 4-
36, plus oral prednisolone initially at dose of 40mg/day, tapered to 7.5mg/day by month 6 of the 
study and continued on this dose until the study end. Those with eGFR of ≥60ml/min/1.73m2 
received glucocorticoid monotherapy for 6 months. They received intravenous 
methylprednisolone (1g/day) as 3 pulsed doses at the start of months 1, 3 and 5 and oral 
prednisolone (0.5mg/kg) every 48 hours on the other days. 
 
The primary outcomes of the study were firstly, full clinical remission defined as proteinuria with 
protein:creatinine ratio of <0.2 and stable renal function with decrease in the eGFR of 
<5ml/min/1.73m2 from the baseline eGFR at the end of the 3 year trial phase and secondly, a 
decrease in the eGFR of at least 15ml/min/1.73m2 from baseline eGFR. 
 
After 3 years, 14 participants in the immunosuppression group met the first primary outcome 
measure of full clinical remission, compared to only 4 participants in the supportive therapy 
alone group. This difference was statistically significant (p=0.01).  However, participants who 
had a full clinical remission had lower baseline levels of proteinuria than those who did not. 
There was no statistical difference in the number of patients in each group having decrease in 
eGFR of at least 15ml/min/1.73m2 (28% in the supportive care group vs. 26% in the 
immunosuppression group) with no significant difference in rate of decline of eGFR between 
groups. 
 
There were more episodes of infection (including one fatal pneumonia) in the 
immunosuppression group, of which 25% were considered directly related to 
immunosuppression. There were also more of episodes of neoplasm; impaired glucose 
metabolism and body weight gain in the immunosuppression arm. 
 
The investigators stated, “We could not confirm our hypothesis that additional 
immunosuppressive therapy would provide substantial kidney-related benefits in patients with 




Approximately one quarter of individuals diagnosed with IgAN with significant proteinuria will 
progress to end stage renal disease (ESRD) requiring dialysis or a kidney transplant within 20-25 
years of presentation.1 The prognosis is worse for those patients with persistent proteinuria.1–3 
In this group approximately 50% may reach ESRD within 10 years.3 IgAN is the most common 
primary glomerulonephritis in the world (including Scotland).1 RAS blockade to aggressively 
control BP and reduce proteinuria is the mainstay of treatment. Current Kidney Disease: 
Improving Global Outcomes (KDIGO) guidelines also recommend use of immunosuppression 
with glucocorticoids if proteinuria remains above 1g/day with maximally tolerated RAS 
blockade.4 However, with the exception of those with nephrotic range proteinuria (>3.5g/day),5 
the evidence base behind this strategy is relatively weak.6 The STOP-IgAN trial addresses this 
area of uncertainty.7 
 
The first piece of knowledge we gain from this study is that, immunosuppression in patients with 
stage 1-3 chronic kidney disease caused by IgAN without nephrotic range proteinuria is of very 
limited benefit in addition to maximal supportive therapy.7 Previous studies, which inform the 
KDIGO guidelines, have shown some benefit from immunosuppressive therapy.4,8–12 However, as 
the STOP-IgAN investigators highlight, these studies lacked a run-in period where RAS blockade 
was maximised, and RAS blockade was either temporarily stopped pre-baseline, or was 
inconsistent throughout the studies.6–12  
 
Further questions remain unanswered about immunosuppresion in IgAN. Firstly, the follow up in 
STOP-IgAN was too short to determine if there is longer-term benefit gained by remission of 
proteinuria, which was achieved in a greater proportion of patients treated with 
immunosuppression.7 Similarly, due to the indolent yet progressive nature of IgAN, patients 
present at different stages in the disease. Some patients may have had haematoproteinuria for 
years prior to diagnosis. For immunosuppresion to be effective, there should be minimal 
irreversible renal fibrosis present. Finally, the individual subgroups treated with the various 
immunosuppressive regimens were small.7 It is also unclear if more specific future 
immunosuppressive regimes (e.g. blisibimod, spleen tyrosine kinase inhibition etc) in the era of 
“precision medicine” may be more effective than the broad based immunosuppressive regimens 
employed in STOP-IgAN. The experience of STOP-IgAN highlights the challenges of testing new 
therapies in IgAN. 
 
Perhaps the real success of this trial is the demonstration that traditional supportive therapy for 
IgAN is effective in the medium term – 34% of participants in STOP-IgAN achieved significant 
reduction in proteinuria.7 With effective RAS blockade and BP control proteinuria can be reduced 
significantly. Furthermore, with reduction in proteinuria one can expect an improved longer-
term prognosis with slower rate of decline of eGFR.7,13 Incredibly mean BP in STOP-IgA was 
126/78mmHg.7 The investigators must be commended on this achievement. Unfortunately real 
life rarely replicates the controlled environment of a clinical trial. This trial7 does provide further 
evidence that we should be aggressively targeting lower BP targets and maximising RAS 
blockade to reduce proteinuria even if, or when, these BP targets are achieved. 
 
It is notable that approximately 42% of randomised participants in STOP-IgAN received both 
ARB and ACEI therapy simultaneously.7 On the back of three recent trials14–16 the UK Medicines 
and Healthcare products Regulatory Agency (MHRA) issued a warning against this combination, 
because of increased risk of hyperkalaemia, hypotension and impaired renal function.17 STOP-
IgAN had only one serious adverse event (in the supportive arm) associated with increased 
serum creatinine and potassium.7 The lack of serious complications of simultaneous ARB and 
ACEI in STOP-IgAN is probably due to intensive study monitoring. In clinical practice, where this 
level of monitoring is impractical, clinicians pursuing dual RAS blockade in this patient group 
would be contravening MHRA advice. We recommend maximal single-agent RAS blockade whilst 
heeding MHRA guidance. 
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